Cencora, Inc. (NYSE:COR) Shares Sold by Brookstone Capital Management

Brookstone Capital Management trimmed its stake in shares of Cencora, Inc. (NYSE:COR) by 6.7% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 3,995 shares of the company’s stock after selling 285 shares during the period. Brookstone Capital Management’s holdings in Cencora were worth $898,000 at the end of the most recent reporting period.

Several other institutional investors have also modified their holdings of the company. Virtu Financial LLC purchased a new stake in Cencora during the second quarter worth $1,086,000. Axxcess Wealth Management LLC boosted its position in shares of Cencora by 5.8% in the 2nd quarter. Axxcess Wealth Management LLC now owns 9,488 shares of the company’s stock worth $2,138,000 after buying an additional 517 shares in the last quarter. SYSTM Wealth Solutions LLC acquired a new stake in Cencora in the 2nd quarter valued at about $36,000. Meiji Yasuda Asset Management Co Ltd. increased its holdings in Cencora by 19.0% during the 2nd quarter. Meiji Yasuda Asset Management Co Ltd. now owns 5,014 shares of the company’s stock valued at $1,130,000 after acquiring an additional 800 shares in the last quarter. Finally, Vanguard Personalized Indexing Management LLC raised its position in Cencora by 6.2% during the second quarter. Vanguard Personalized Indexing Management LLC now owns 21,366 shares of the company’s stock worth $4,781,000 after acquiring an additional 1,248 shares during the last quarter. Hedge funds and other institutional investors own 97.52% of the company’s stock.

Analyst Upgrades and Downgrades

Several analysts have recently commented on the stock. Wells Fargo & Company lowered their price target on shares of Cencora from $249.00 to $237.00 and set an “equal weight” rating on the stock in a research report on Friday, December 13th. Leerink Partners lowered their target price on Cencora from $277.00 to $275.00 and set an “outperform” rating on the stock in a report on Monday, October 7th. Evercore ISI upped their price objective on Cencora from $250.00 to $285.00 and gave the company an “outperform” rating in a research report on Thursday, November 7th. Mizuho assumed coverage on Cencora in a research note on Wednesday, December 4th. They set an “outperform” rating and a $280.00 price objective on the stock. Finally, StockNews.com downgraded shares of Cencora from a “strong-buy” rating to a “buy” rating in a research note on Friday, September 20th. Two equities research analysts have rated the stock with a hold rating and ten have given a buy rating to the stock. Based on data from MarketBeat, Cencora has a consensus rating of “Moderate Buy” and a consensus target price of $275.60.

Insider Buying and Selling

In other Cencora news, EVP Silvana Battaglia sold 1,678 shares of the business’s stock in a transaction dated Friday, December 20th. The stock was sold at an average price of $228.72, for a total transaction of $383,792.16. Following the completion of the sale, the executive vice president now owns 20,329 shares of the company’s stock, valued at approximately $4,649,648.88. The trade was a 7.62 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Chairman Steven H. Collis sold 21,509 shares of the firm’s stock in a transaction dated Tuesday, October 22nd. The stock was sold at an average price of $235.80, for a total value of $5,071,822.20. Following the completion of the transaction, the chairman now owns 285,088 shares in the company, valued at approximately $67,223,750.40. This trade represents a 7.02 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last quarter, insiders sold 94,696 shares of company stock valued at $22,862,734. Insiders own 15.80% of the company’s stock.

Cencora Stock Up 1.2 %

Shares of NYSE:COR opened at $240.51 on Friday. Cencora, Inc. has a 12-month low of $214.77 and a 12-month high of $253.27. The stock’s 50-day moving average price is $237.65 and its two-hundred day moving average price is $233.72. The company has a current ratio of 0.88, a quick ratio of 0.53 and a debt-to-equity ratio of 4.84. The firm has a market cap of $46.49 billion, a price-to-earnings ratio of 32.03, a PEG ratio of 1.48 and a beta of 0.49.

Cencora Increases Dividend

The business also recently announced a quarterly dividend, which was paid on Friday, November 29th. Investors of record on Friday, November 15th were issued a $0.55 dividend. This represents a $2.20 dividend on an annualized basis and a yield of 0.91%. This is an increase from Cencora’s previous quarterly dividend of $0.51. The ex-dividend date was Friday, November 15th. Cencora’s payout ratio is presently 29.29%.

Cencora Profile

Cencora, Inc sources and distributes pharmaceutical products. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers.